|
ABOUT COMPANY
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on itching and pain by selectively targeting kappa opioid receptors in the United States. The company is headquartered in Stamford, Connecticut.
|
EARNINGS
Gross Profit (TTM): 27231000
Market Capitalization: 651127000
Operating Margin (TTM): 0.169
PE Ratio: 25.43
PEG Ratio: 0
Profit Margin: 0.178
Revenue Per Share (TTM): 2.695
Revenue (TTM): 134296000
Quarterly Earnings Growth YOY: 0
Quarterly Revenue Growth YOY: 1.188
Trailing PE: 25.43
|
DIVIDENDS
Diluted EPS (TTM): 0.479
Dividend Date: None
Dividend Per Share: None
Dividend Yield: 0%
EBITDA: 22977000
ExDividend Date: None
Forward Annual Dividend Rate:
Forward Annual Dividend Yield:
|